Fig. 1From: Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cellsClinical response to elraglusib monotherapy in a patient with refractory melanoma. 54-year-old male with BRAFV600E refractory melanoma and multiple sites of disease, including multiple brain lesions and progressing on anti PD-1 plus BRAF/MEK inhibitor combination. After 4-week washout brain lesions progression evident on MRI. The patient was treated with single-agent elraglusib at 5Â mg/kg and within 6Â weeks most sites of disease had resolved by PET, as well as significant CNS tumour shrinkage. Post-12Â weeks of therapy, there was complete resolution of lesions by PET and only cystic lesions noted on brain MRI. The patient continues in CR for over 36Â monthsBack to article page